Articles tagged with Hormone Therapy
A new Fox Chase Cancer Center study suggests men with early stage prostate cancer treated with radiation therapy should begin hormone therapy immediately if their PSA level rises quickly and doubles within six months at any time after treatment. The study also supports foregoing hormones if the PSA doesn't rise as quickly. These findin...
A large cohort study found that hormone therapy before radiation seed implants for prostate cancer increases the risk of death by 20% in men over 70 years old with early-stage cancer. This treatment approach may have negative effects on survival, particularly for older patients.
Researchers at Fox Chase Cancer Center have developed a prediction tool that estimates the benefit of adding androgen deprivation therapy to radiation therapy for high-risk prostate cancer patients. The tool takes into account disease burden and individual patient characteristics, allowing for personalized treatment recommendations.
Researchers developed a preoperative endocrine prognostic index (PEPI) to predict relapse risk in women with stage 2 or 3 estrogen receptor-positive breast cancer. The model incorporates tumor characteristics and is statistically significant in predicting relapse-free survival.
A new predictive measurement, called a PEPI score, can help determine the treatment of breast cancer patients. A low PEPI score indicates little risk of relapse and allows patients to safely avoid chemotherapy after surgery. Women with high PEPI scores are at high risk of having their cancer return and require aggressive therapy.
A randomized clinical trial shows acupuncture reduces hot flashes and vasomotor symptoms in breast cancer patients, providing additional benefits like increased energy and well-being. The treatment has no side effects compared to commonly used drugs.
A randomized study found that adding radiation therapy to hormone treatment reduces the risk of dying from prostate cancer by 50% compared to hormone therapy alone. The quality of life at four years after treatment was similar between the two groups, with decreased social function in patients who received combined treatment.
A study found that estrogen therapy reduced the risk of fractures after menopause, particularly in women aged 50-64 years. The use of post-menopausal hormone replacement therapy increased greatly during this period and was estimated to cause nearly half of the decline in fracture rates among women.
Research from Michigan Medicine found that estrogen treatments stimulate collagen production in non-sun damaged skin, but have no effect on sun-damaged skin. The study suggests it's difficult to repair photoaged skin due to altered skin response to topical estrogen treatment.
Researchers at Mount Sinai Hospital have developed a new once-weekly treatment for type 2 diabetes that mimics the action of GLP-1, a naturally occurring hormone. The treatment showed significant improvements in glucose control and reduced side effects compared to twice-daily injections.
A large trial found significant improvements in quality of life, sleep and joint pain for post-menopausal women on hormone replacement therapy. Researchers also noted improved sexuality among participants.
Researchers have found that a common treatment for advanced prostate cancer can actually cause some cancer cells to grow, rather than stopping them. The androgen receptor plays a versatile role in the disease, acting as both a tumor promoter and suppressor in different cell types.
Despite five years of systemic therapy, breast cancer patients remain at risk for disease recurrence. Women with hormone receptor-positive cancer have a higher risk of relapse, highlighting an unmet clinical need for new strategies to reduce this risk.
A retrospective analysis of postmenopausal women with early-stage breast cancer found that previous use of hormone replacement therapy (HRT), hormone-receptor positivity, and treatment with anastrozole versus tamoxifen were associated with joint symptoms. Obesity was also linked to increased joint symptoms in these patients.
Research suggests that increased testosterone in male mice increases their ability to transmit diseases, driving transmission through close social contact. The study found that treated mice made significantly more contacts with both males and females than untreated mice, leading to a higher risk of disease spread.
Asterion Ltd.'s patented ProFuse technology enables the creation of longer-acting drugs to tackle major diseases. The company's platform can also be used to develop pairings between therapeutic hormones and protective receptor domains to address conditions like some cancers, anaemia, infertility, and diabetes.
A randomized, double-blind study involving 102 women with schizophrenia found that estrogen estradiol improved psychotic symptoms more effectively than antipsychotic medications alone. No significant difference was observed in negative symptoms, suggesting potential for longer-term treatment or alternative approaches.
A low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in HIV patients with lipodystrophy. However, growth hormone treatment appeared to increase blood glucose levels, particularly in those with impaired glucose tolerance.
A recent review of literature found that hormone deprivation therapy can have subtle adverse effects on cognition in prostate cancer patients, affecting recall, concentration, and high-order capacities. Between 47% and 69% of men treated with androgen depletion therapy decline in cognitive function.
A recent review of the literature found that hormone deprivation therapy can have subtle adverse effects on cognition in prostate cancer patients. Studies indicate that between 47% and 69% of men treated with androgen depletion therapy decline in at least one cognitive area, primarily in spatial ability and high-order capacities.
For elderly men with localized prostate cancer, androgen deprivation therapy does not improve survival rates compared to conservative management. The study found lower 10-year prostate cancer-specific survival rates among those using PADT.
Men with breast cancer often experience poor outcomes due to delayed diagnoses, with 50% of cases reaching advanced stages. Early detection and treatment are crucial, as hormone therapy can be highly effective in treating the disease.
Difficulty sleeping and waking up early are more common in certain ethnic groups during menopause. The study found that Caucasian women were more likely to experience difficulty staying asleep, while Hispanic women were less likely to wake up frequently at night.
The Damon Runyon Cancer Research Foundation has awarded $2.25M to five outstanding young clinical investigators, including Dr. Ronald Buckanovich, Andrew Chan, Rachael Clark, Vassiliki Karantza-Wadsworth, and Elahe Mostaghel, to support their cancer research programs.
Restoring normal testosterone levels in hypogonadal men leads to major improvements in metabolic syndrome features. Older men (63+) benefit equally as younger men from testosterone treatment, according to studies presented at The Endocrine Society's 90th Annual Meeting.
A study found that radiation treatment after radical prostatectomy was associated with a significant increase in prostate cancer-specific and overall survival. Men with rapid PSA doubling time or high Gleason score benefited from early salvage radiotherapy, which improved survival by over 75%.
Researchers found that hormone replacement therapy maintained coronary endothelial function, while those without HRT experienced worsening endothelium function. Postmenopausal women who gave up HRT demonstrated the most severe drop in endothelial function.
A new animal study suggests that estrogen treatment is not toxic per se, but its effects on the brain depend on an individual's reproductive age. In rats, estrogen therapy reduced brain damage when given before menopause, but increased it after, highlighting a narrow window of time for neuroprotective benefits.
Women who have taken menopausal hormone therapy before are at a 37% higher risk of breast cancer than those who never used it. The risk is highest when taking combined estrogen and progestin therapies, with an increased risk by 73% during use.
Low testosterone levels in men are often untreated, even among those with sufficient healthcare access, according to a study of Boston-area men. Despite this, treated and untreated men report similar healthcare visits, suggesting barriers may lie in diagnosis or prescription issues.
A new analysis suggests that healthy postmenopausal women with normal blood cholesterol levels are at no increased short-term risk for heart attack when taking hormone therapy. Women with a low LDL to HDL ratio have an even lower risk of heart attack or death from hormone therapy.
A research study has found that a simple blood test can indicate whether post-menopausal hormone therapies increase the risk of a heart attack. Women with favorable cholesterol levels were not at increased risk of developing heart problems while taking hormones, whereas those with unfavorable cholesterol levels were at higher risk.
Researchers have identified a unique genetic signature that can alert physicians to high-risk breast tumors masquerading as low-risk tumors. The genetic signature is associated with a higher chance of cancer recurrence and standard anti-estrogen therapy being ineffective.
A Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center found that Iressa enhanced the effectiveness of hormonal therapy in treating specific types of metastatic breast cancer. The combination resulted in a 45% reduction in risk and improved clinical benefits for patients.
A study of 121,700 women found that postmenopausal hormone therapy is associated with a higher risk of stroke, even in younger women taking hormones near menopause. The risk was strongest for those taking larger doses and longer durations of hormone therapy.
Researchers found that hormone therapy started around menopause onset may have similar benefits as those without risk factors for heart disease. The study suggests that current guidelines may need to be revised for younger women taking hormone therapy.
A study found that testosterone spray increased frequency of sexually satisfying events in premenopausal women, but the effect was only significant for the middle dose. Conventional treatments like cognitive behavioral therapy and sex therapy are recommended over hormone replacement therapy.
Two studies published in Blood journal provide insights into the regulation of red blood cell production, linking it to the Hls5 gene and thyroid hormone. This knowledge may lead to new treatments for anaemias that don't respond to current hormone therapy.
Preliminary study results show testosterone administration reduces bone turnover, with potential protective effects on existing bone mass. Testosterone replacement therapy may benefit older men with low-to-normal testosterone concentrations.
A new study in mice found that moderate and high doses of estrogen replacement therapy increased problems in the kidney and heart. The results suggest that ERT dosage may be an important determinant in a woman's overall health.
A new study has found that hormone replacement therapy (HRT) increases the risk of breast cancer recurrence in women who have survived breast cancer. The HABITS trial, which followed over 200 breast cancer survivors for four years, found that HRT significantly increased the risk of disease recurrence.
Regular aerobic exercise significantly decreases oxidative stress levels and improves cardiovascular health in postmenopausal women. The study found that both HRT users and non-users benefited equally from the exercise program, reducing the risk of heart disease and stroke.
Researchers found that MPA decreased endothelial function in premenopausal women, raising questions about long-term effects on cardiovascular health. The study suggests that exposure to synthetic hormones may reduce blood vessel flexibility, potentially leading to heart disease.
A recent study found that post-menopausal women who stopped taking combined hormone therapy experienced an increased risk of all cancers, including lung cancer. The research, led by Rowan T. Chlebowski, confirms previous findings on the risks of hormone therapy.
A follow-up study of women who stopped taking hormone therapy after a clinical trial found an increased risk of cancer, with higher rates of invasive breast cancer and other cancers. Cardiovascular events were comparable between the two groups.
A follow-up study of WHI participants found an increased risk of invasive breast cancer and other cancers in women taking estrogen plus progestin. The risk of heart disease, stroke, and blood clots decreased after the intervention was stopped.
A follow-up study of the Women's Health Initiative confirms that long-term use of combination hormone therapy in healthy postmenopausal women increases risks of heart disease, stroke, and blood clots. After stopping hormone therapy, cardiovascular disease risk decreases but overall risks remain high.
A study of 3,987 older men found that those with low free testosterone levels had a higher prevalence of depression, with men in the lowest quintile having three times the odds of depression compared to those in the highest quintile. Researchers suggest that hormone imbalances may contribute to this link.
Researchers at Thomas Jefferson University have discovered that blocking the signaling protein Stat5 can effectively kill prostate cancer cells and inhibit tumor growth. This finding holds promise for treating advanced prostate cancer, particularly hormone-resistant cases.
Researchers have found that hormone replacement therapy does not significantly affect the risk of developing or exacerbating rheumatoid arthritis. The study analyzed data from over 27,000 postmenopausal women taking part in a clinical trial, revealing no notable differences between those on hormone replacement therapy and placebo groups.
Researchers have discovered that heart hormones can eliminate human pancreatic and breast cancers in mice, reducing tumors by up to 97%. The treatment has shown no side effects and has the potential to make cancer a chronic condition.
A recent study published in Archives of Internal Medicine found that combined hormone therapy significantly increases the risk of abnormal mammograms and breast biopsies, compromising their diagnostic performance. The research involved 16,608 post-menopausal women and revealed a four percent greater risk of mammogram abnormalities afte...
Researchers at Gladstone and UCSF found that growth hormone therapy stimulates the production of vital T-cells, leading to increased thymic mass and improved immune function. The study suggests that this treatment could help HIV-infected patients rebuild their compromised immune systems.
Researchers are developing new drugs that can modulate male hormone receptors to improve muscle weight without stimulating prostate glands. Studies have shed light on the complex mechanisms behind estrogen receptors in different tissues.
Men with localized prostate cancer who received male hormone suppression therapy and radiation treatment had longer survival rates. However, those with moderate to high levels of comorbid illnesses did not experience this effect. Combination therapy improved overall survival in men without severe comorbidity.
Postmenopausal women taking combined estrogen/progestin hormone-replacement therapy for three years or more face a significant increased risk of developing various forms of lobular breast cancer. The study, which confirms previous reports, suggests that even short exposure to such hormones may confer an increased risk.
Researchers discovered that Gas6 protein increases cell signaling in response to Epo treatment, enhancing its therapeutic potential for treating anemia. The study also found that mice deficient in Gas6 have decreased sensitivity to Epo and reduced ability to recover from anemia.
Researchers found that a short course of hormonal therapy before and with radiation therapy slowed cancer growth by up to eight years, particularly the development of bone metastases. This delayed cancer progression increased survival rates among older men with potentially aggressive prostate cancer.
Researchers at Thomas Jefferson University have found that nearly all recurrent prostate cancers resistant to hormone therapy activate a signaling protein called Stat5, making it a potential drug target. The convergence of two biological pathways may also contribute to the development of aggressive hormone-resistant tumors.
Researchers argue that female sex hormones play a critical role in mood disorders, and studies are needed to understand their effects. Hormonal fluctuations during times of menstruation or menopause may contribute to the increased vulnerability of women to poor mental health.